Update on Antimicrobial Susceptibility Rates Among Gram-Negative and Gram-Positive Organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007
Update on Antimicrobial Susceptibility Rates Among Gram-Negative and Gram-Positive Organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007
复制标题
DOI：
10.1016/j.clinthera.2008.11.006
复制
发表时间：
2008-11-01
影响因子：
3.2
通讯作者：
Park, Chocing H.
中科院分区：
文献类型：
--
作者：
Dowzicky, Michael J.;Park, Chocing H.
背景：替加环素评价和监测试验（TEST）是2004年启动的一项全球监测研究。其目的是评估体外活性的甘环素，替加环素和比较抗菌剂。目的：本研究的目的是测定2005年、2006年和2007年在美国收集的一组抗革兰氏阴性和革兰氏阳性微生物的体外活性。方法：从美国172个中心收集分离株。体外活性评估采用临床和实验室标准协会（CLSI）指南和CLSI或美国食品和药物管理局的解释标准。结果：共收集革兰氏阴性株20,897株和革兰氏阳性株8949株。对于大多数生物，敏感性百分比在3年的收集期间没有变化。一个例外是鲍曼不动杆菌；在3年中，对大多数药物的易感性率下降了大约10%。产生广谱β -内酰胺酶（ESBL）的肺炎克雷伯菌的耐药表型率相对不变，3年内的平均百分比为8.9% (337/3787)；产esbl的克雷伯菌（Klebsiella oxytoca）为2.1% (17/801)；产esbl的大肠杆菌2.3%,(111/4861)；耐甲氧西林金黄色葡萄球菌56.2% (2564/4560)；耐万古霉素粪肠球菌5.1% (97/1903)；耐万古霉素屎肠球菌67.2%（487/725）。替加环素抑制90%微生物生长所需的抑制浓度（MIC90）在3年内稳定，为
Background: The Tigecycline Evaluation and Surveillance Trial (TEST) is a global Surveillance study initiated in 2004. Its goal is to assess the in vitro activity of the glycylcycline, tigecycline, and comparator antimicrobials.Objective: The aim Of this Study was to measure the in vitro activity of a panel of antimicrobial agents against gram-negative and gram-positive Organisms collected in the United States in 2005, 2006, and 2007.Methods: Isolates were collected from 172 centers across the United States. In vitro activity was assessed using Clinical and Laboratory Standards Institute (CLSI) guidelines and CLSI or US Food and Drug Administration interpretive criteria.Results: Overall, data on 20,897 gram-negative and 8949 gram-positive isolates were collected. For the majority of Organisms, percentage Susceptibilities were unchanged over the 3 years of collection. One exception was Acinetobacter baumannii; rates Of susceptibility to the majority of agents in the panel decreased by similar to 10% over the 3 years. Rates of resistant phenotypes were relatively unchanged with mean percentages over the 3 years of: 8.9%, (337/3787) for extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae; 2.1% (17/801) for ESBL-producing Klebsiella oxytoca; 2.3%, (111/4861) for ESBL-producing Escherichia coli; 56.2% (2564/4560) for methicillin-resistant Staphylococcus aureus; 5.1% (97/1903) for vancomycin-resistant Enterococcus faecalis; and 67.2% (487/725) for vancomycin-resistant Enterococcus faecium. The inhibitory concentration required to Inhibit the growth of 90% of Organisms (MIC90) for tigecycline was stable over the 3 years and was